A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial).

Geert A. Cirkel,Paul Hamberg,Stefan Sleijfer,Olaf Loosveld,Wouter Dercksen,Maartje Los,John B. A. G. Haanen,Marco B. Polee,Franchette van den Berkmortel,Maureen J. Aarts,Laurens V. Beerepoot,Gerard Groenewegen,Martijn P. Lolkema,Metin Tascilar,Johanna Elisabeth A. Portielje,Frank P. J. Peters,Heinz-Josef Klümpen,Vincent van de Noort,Emile E. Voest

A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial).

2016

Geert A. Cirkel
Paul Hamberg
Stefan Sleijfer
Olaf Loosveld
Wouter Dercksen
Maartje Los
John B. A. G. Haanen
Marco B. Polee
Franchette van den Berkmortel
Maureen J. Aarts
Laurens V. Beerepoot
Gerard Groenewegen
Martijn P. Lolkema
Metin Tascilar
Johanna Elisabeth A. Portielje
Frank P. J. Peters
Heinz-Josef Klümpen
Vincent van de Noort
Emile E. Voest

4550Background: Targeted agents have improved survival in ccRCC patients but resistance always develops. Since accumulating evidence suggests that resistance is partially reversible after drug with...

Keywords:

Sequential treatment
Pazopanib
Phases of clinical research
Cell
Clear cell
Pathology
Everolimus
Oncology
Cancer
Internal medicine
Medicine
second line
first line
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations